\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Corporate Profile

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Three clinical programs are advancing and demonstrating the safety and efficacy of onvansertib: Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated metastatic colorectal cancer (mCRC); Phase 2 study of onvansertib in combination with Zytiga® (abirterone)/prednisone in Zytiga-resistant metastatic castration-resistant prostate cancer (mCRPC); and Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML).

Company Overview (button) - January 2022
Recent News
Jan 18, 2022

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical...

Jan 11, 2022

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical...

Jan 10, 2022

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical...

More >

Stock Information
NASDAQCRDF
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@cardiffoncology.com

Contact

Events
January 18, 2022
5:00pm - 5:30pm EST

Cardiff Oncology management will host a webcast and conference call to present the most recent data from its Phase 1b/2 trial in KRAS-mutated mCRC. To...

January 10, 2022 - January 13, 2022

Cardiff Oncology CEO, Mark Erlander, PhD, will present at the H.C. Wainwright BioConnect virtual conference. The presentation will be available on-demand Monday, January 10th through Wednesday,...

November 17, 2021

Mark Erlander, Ph.D., chief executive officer of Cardiff Oncology, will present and participate in virtual 1x1 investor meetings at the Jefferies London Healthcare Conference on November 18th, 2021.